Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Wrap it Up! Neuregulin Directs Axonal Myelination
26 March 2004. How do Schwann cells know how much myelin to wrap around an axon during development? It's not a trivial problem—a small difference in myelin thickness can change signal transduction speed through the axon, with potentially devastating consequences for organism survival. According to a report published March 25 in ScienceExpress by German and U.S. researchers, axons use neuregulin-1 to signal how much myelin they require—a message that is relayed within the Schwann cells by erbB receptor tyrosine kinases.

With hints that white matter decay could be an early and contributing factor in Alzheimer's disease, myelin has become a focus of some AD researchers (for review, see Bartzokis, 2004). This is bringing attention to bear on molecules important for the formation of myelin, among them the many variants of neuregulin and erbB.

By creating mice with reduced gene dosages of the genes for neuregulin-1 or variations of erbB, as well as heterozygous combinations of these, Klaus-Armin Nave of the Max Planck Institute of Experimental Medicine in Gottingen, Germany, and his colleagues found that reductions in neuregulin-1 (type III) and erbB2 proteins were correlated with reduced myelination of peripheral axons. While the mice were behaviorally normal, nerve conduction velocity was reduced. Neuregulin-1 was determined to be the rate-limiting parameter, as reductions in gene dosage of erbB2 alone did not reduce myelin thickness.

Conversely, neuregulin-1 overexpression in transgenic mice resulted in thicker myelin around peripheral axons. "Although we cannot rule out the participation of additional axonal signals and growth factors, NRG-1 type III emerges as a critical regulator of Schwann cell myelin thickness," note the authors.

The links between myelin construction and maintenance and Alzheimer's disease remain murky. NRG-1 and the erbB family of receptors continue to be expressed in aging human brain, and it has been shown both that the distribution of expression changes in AD and that erbB4 and NRG-1 are associated with neuritic plaques (Chaudhury et al., 2003). In addition, Notch works some of its developmental effects via erbB2 and neuregulin signaling (see ARF related news story). We invite your speculations on these connections.—Hakon Heimer.

Reference:
Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave K-A. Axonal neurogulin-1 regulates myelin sheath thickness. ScienceExpress. 2004 Mar 25. DOI 10.1126/science.1095862. Abstract

 
Comments on News and Primary Papers
  Comment by:  Gabriel Corfas
Submitted 30 March 2004  |  Permalink Posted 30 March 2004

Comment by Gabriel Corfas, Kristine Roy, and Suzhen Chen
Over the last decade, evidence implicating the growth factor neuregulin 1 (NRG1) and its receptors, the erbB tyrosine kinases, in myelination of the peripheral nervous system has been accumulating. The early studies examined the consequences of loss of NRG1-erbB function. For example, Garratt et al. (2000) showed that ablation of erbB2 in Schwann cells results in reductions of the number of Schwann cell precursors in the developing nerve and hypomyelination of sciatic nerve axons in the adult. Now, a paper by Nave's group (Michailov et al., 2004) has extended these findings by examining the outcome of both reductions and increases of NRG1-erbB signaling on myelin formation. As expected from the preceding evidence, this study found that reduction in NRG1 or erbB2 expression results in hypomyelination. The more surprising finding in this study is that overexpression of NRG1 in axons leads to increased myelin thickness in the sciatic nerve. These results indicate that NRG1 is part of the signaling mechanisms by...  Read more

  Comment by:  George Bartzokis
Submitted 2 April 2004  |  Permalink Posted 2 April 2004

Being human and the myelin on small fibers: Implications for the dementias and multiple other neuropsychiatric disorders
By examining mice, Michailov et al. (2004) might have given us an important lead about the mechanisms that make our brain (and the disorders that plague it) unique.

The human brain is unique in its high myelin content and long developmental (myelination) phase that continues until approximately the age of 50 (Bartzokis et al., 2001). Although our extensive process of myelination underlies many of our brain’s unique capabilities, it likely also underlies its unique susceptibility to highly prevalent disorders of development (autism, ADHD, schizophrenia, drug use, depression), as well as degeneration (Alzheimer’s, Parkinson’s, Lewy body and other rarer diseases) (Bartzokis, 2004a, 2004b). The large axons on which primary processes (motor and sensory) depend myelinate fully and most extensively in infancy, and are largely spared in both developmental and degenerative brain diseases despite their size and high metabolic requirements. On the other...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad